Harbor-IN: License-Free Transposase for High-Titer Biologics Production

Biopharmaceutical production demands precision, efficiency, and scalability. Traditional methods such as viral vectors and random plasmid integration introduce challenges related to genomic stability, immunogenicity, and low productivity. Harbor-IN, a license free transposase system, overcomes these hurdles by enabling stable, and high-efficiency gene integration into genomic regions optimized for robust and sustained expression.

Unlock the Full Potential of Biologics Manufacturing

Harbor-IN is uniquely suited for bioproduction, streamlining cell line development and enabling high-titer protein expression without the need for labor-intensive process intensification strategies.

  • Achieve Titers >8 g/L – Demonstrated in CHO cells expressing monoclonal antibodies under GS selection.
  • Non-Viral, Stable Integration – Avoids the risks associated with viral vectors, ensuring regulatory compliance and genomic integrity.
  • Flexible Cargo Capacity – Efficiently integrates large genetic payloads (>200 kb).

License-Free Commercial Use: Freedom to Operate

Unlike many transposases that require time consuming and expensive licensing agreements, Harbor-IN is available for unrestricted commercial use. With the purchase of Harbor-IN, companies gain full access to a powerful transposase system for applications in cell line development, bioprocessing—without any additional fees.

How It Works

Harbor-IN integrates genetic material into safe genomic sites, favoring highly transcribed, open chromatin regions for maximal and stable gene expression.

Harbor-IN Starter Kit: Fast-Track Your Development

The Harbor-IN Starter Kit includes:

  • Optimized mRNA Transposase (25 µg) for efficient genomic integration
  • Four Pre-Validated Transposon Plasmids for streamlined selection and expression
  • Transposon plasmids possess multiple cloning sites (MCS) for efficient cloning

Combine Harbor-IN with our Biologics Expression Platforms

Whether you’re developing monoclonal antibodies or other recombinant proteins, Harbor-IN provides a scalable, efficient, and cost-effective solution for stable gene integration—without licensing barriers.

Harbor-IN is fully compatible with Demeetra’s CleanCut GS CHO cell platform, enabling high-efficiency, stable gene integration for biologics production. This combined system has demonstrated industry-leading cell-specific productivity, optimizing recombinant protein expression. Further platform enhancements can be achieved through Cas-CLOVER targeted nuclease technology, facilitating precise knock-ins at high-expression genomic loci to further enhance productivity and downstream processes.

Optimizing Your Gene Editing Research?

Contact us to learn more about our innovative gene editing technology.